Tirzepatide 5mg
Certificate of Analysis available
Tirzepatide
CAS # 2023788-19-2
Mol. weight 4813.11 g/mol
Formula C225H348N48O68
Identity
Manufacturer Generic Peptides
Active substance Tirzepatide (dual GIP/GLP-1 receptor agonist, "twincretin")
Synonyms LY3298176, GIP/GLP-1 RA, TZP, Twincretin, Mounjaro, Zepbound
Composition
Form Lyophilized powder
Purity ≥ 99% HPLC
Sequence Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(γGlu-2×AEEA-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 aa)
Product usage — Research only
- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
The SURMOUNT-5 head-to-head trial gave the field its answer. Over 72 weeks, tirzepatide-treated patients achieved a mean body weight reduction of 20.2%. Semaglutide-treated patients achieved 13.7%. That's a 47% greater relative weight loss with tirzepatide. The single most-watched comparison in obesity medicine settled the question: activating two incretin receptors works substantially better than activating one. The pharmacology behind that result is the entire story of why Eli Lilly's compound rewrote the field.
What Is Tirzepatide?
Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide engineered to activate two distinct incretin receptors simultaneously: the GLP-1 receptor (the same one Semaglutide targets) and the GIP receptor (glucose-dependent insulinotropic polypeptide). Both are G protein-coupled receptors expressed in pancreatic β-cells, the central nervous system, and metabolic tissues. The dual agonism is what makes the compound mechanistically unique — and what produces the larger metabolic effects observed in clinical trials.
The structural engineering is similar to Semaglutide's approach: a fatty acid attachment (specifically, a C20 dicarboxylic acid via a γ-Glu spacer) binds serum albumin and extends half-life to roughly 5 days. This makes once-weekly dosing practical. But unlike Semaglutide, tirzepatide's amino acid sequence is closer to natural GIP than to GLP-1 — and recent pharmacological research suggests it acts as an "imbalanced" or "biased" dual agonist with somewhat greater receptor occupancy at GIP than GLP-1 at therapeutic concentrations. That asymmetry is part of why the metabolic effects differ from pure GLP-1 monotherapy.
The Dual Receptor Mechanism That Changed the Field
GLP-1 and GIP are both natural incretin hormones — gut-released signals that trigger insulin secretion in response to nutrient ingestion. They've been studied separately for decades. Selective GLP-1 agonism became the foundation of modern diabetes and obesity pharmacology (Liraglutide, Semaglutide, others). GIP, by contrast, has had a complicated history. In type 2 diabetes, GIP signaling is partially impaired, and earlier research suggested GIP receptor activation might worsen rather than improve glucose control. Tirzepatide's clinical performance contradicted that older assumption.
The combined activation produces effects that exceed pure GLP-1 monotherapy: stronger pancreatic insulin secretion (GLP-1 + GIP synergy at β-cells), enhanced GIP-driven white adipose tissue function, integrated anorexigenic signaling at hypothalamic and brainstem appetite-control centers, and improved insulin sensitivity beyond what's explained by weight loss alone. The 30% normoglycemia rate at 15 mg in the Phase 2b trial — patients reaching HbA1c below 5.7% — was unprecedented for an antidiabetic medication. The 22-26% mean weight loss in the SURMOUNT obesity trials similarly exceeded prior obesity pharmacotherapy benchmarks.
What Serious Buyers Should Know
Here's the uncomfortable truth: tirzepatide's gastrointestinal side effects are real and pronounced. Nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal discomfort are dose-dependent and most pronounced during titration. Most patients tolerate them; a meaningful minority don't. The compound carries a thyroid C-cell tumor warning based on rodent studies, plus pancreatitis and gallbladder warnings consistent with the GLP-1 class. Severe gastroparesis and significant cardiovascular conditions are contraindications.
The compound also currently lacks the long-term cardiovascular outcome data that Semaglutide has accumulated through trials like SELECT. The SURPASS-CVOT trial is ongoing. For now, tirzepatide's documented benefits are substantial; its long-term safety database is still building.
Regulatory note: Tirzepatide is an FDA-approved prescription drug with multiple indications. Mounjaro (type 2 diabetes) was approved May 2022; Zepbound (chronic weight management) was approved November 2023; the obstructive sleep apnea indication was added December 2024. The compound was on the FDA's drug shortage list during 2023-2024, allowing 503A and 503B compounding pharmacy production. The shortage was resolved in late 2024, narrowing compounding pathways significantly. As of May 2026, brand-name tirzepatide is available through approved channels for human use, with limited 503A compounding for documented patient-specific clinical need. Sales as a research compound continue legally for laboratory use. WADA's Prohibited List does not currently include tirzepatide.
Why Generic Peptides for Tirzepatide?
Here's a sourcing problem that's specific to tirzepatide: it's a 39-amino-acid peptide with a complex C20 dicarboxylic acid attachment via a γ-glutamic acid spacer — essentially the same fatty acid attachment principle as Semaglutide but applied to a longer, more complex peptide backbone. The fatty acid conjugation chemistry is the technically demanding, expensive part of the synthesis, and it's what produces the 5-day half-life that makes weekly dosing practical. Cheap synthesis routes routinely deliver under-conjugated material with reduced albumin binding affinity, fatty acid attached at the wrong position, or unmodified peptide mislabeled as tirzepatide. The compound looks correct on a label but doesn't behave like FDA-approved Mounjaro/Zepbound. The international counterfeit market for GLP-1 drugs has been documented in safety alerts by health authorities across multiple countries. Without analytical verification of fatty acid conjugation, you may have a peptide that's structurally close to tirzepatide but pharmacokinetically wrong.
Generic Peptides supplies research-grade Tirzepatide for sale at 99% purity, manufactured in the USA. Domestic synthesis with verified fatty acid conjugation — the part that determines whether you have actual tirzepatide pharmacokinetics or accidentally-purchased-something-else pharmacokinetics.
Order Tirzepatide for sale in the USA — 99% purity, fatty acid conjugation verified, manufactured domestically.
Tirzepatide FAQ
Is it legal to buy Tirzepatide in the US for research?
Yes — Tirzepatide is legally available for laboratory research use in the United States. As an FDA-approved prescription drug under the brand names Mounjaro (diabetes) and Zepbound (obesity, OSA), it requires a prescription for human use through approved channels. Sales as a research compound for laboratory work exist in a separate regulatory channel. WADA does not currently list tirzepatide as prohibited.
What's the difference between Mounjaro and Zepbound?
Same active ingredient (tirzepatide), different FDA-approved indications and dosing strategies. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Both are weekly subcutaneous injections from Eli Lilly. The molecule is identical; the regulatory and clinical contexts differ.
How does Tirzepatide differ from Semaglutide?
Receptor selectivity. Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates both incretin receptor pathways simultaneously. The SURMOUNT-5 head-to-head trial (NEJM, 2025) demonstrated 47% greater relative weight loss with tirzepatide (20.2% vs 13.7% mean weight reduction at 72 weeks). The dual mechanism produces broader metabolic effects.
Why does Tirzepatide produce more weight loss than other GLP-1 drugs?
The dual GIP/GLP-1 mechanism. GIP receptor activation contributes to white adipose tissue function and provides additional anorexigenic signaling at central appetite centers. The "imbalanced" dual agonism — somewhat greater GIP than GLP-1 receptor occupancy at therapeutic concentrations — produces effects that pure GLP-1 monotherapy can't replicate. Multiple pharmacological pathways converging is what drives the larger magnitude of effect.
I've seen Tirzepatide sold cheap online — same product?
Probably not at the same purity or fatty acid conjugation quality. The international counterfeit GLP-1 drug market is well-documented in health authority safety alerts. The C20 fatty acid attachment chemistry is technically demanding, and cheap synthesis routinely delivers under-conjugated or improperly-conjugated material. Without analytical verification, you may be buying a peptide labeled correctly but pharmacokinetically different from FDA-approved tirzepatide.
Sources
Frias JP et al. — "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." NEJM, 2021. The foundational head-to-head efficacy trial. https://pubmed.ncbi.nlm.nih.gov/34170647/
Aronne LJ et al. — "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)." NEJM, 2025. Head-to-head comparison documenting 20.2% vs 13.7% weight reduction — 47% greater relative weight loss with tirzepatide over 72 weeks. https://pubmed.ncbi.nlm.nih.gov/40353578/
Willard FS et al. — "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight, 2020. Documents the receptor occupancy asymmetry and dual agonist pharmacology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526454/
FDA — Mounjaro (May 2022) and Zepbound (November 2023) approval announcements. Documents the FDA-approved indications, mechanisms, and clinical trial data supporting tirzepatide. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Two receptors, one peptide. The fatty acid conjugation is what makes it work. Sourcing matters.
Tirzepatide Storage Guide: How to Keep Your Research Peptide Stable and Effective
Tirzepatide ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve this 39-amino-acid dual GIP/GLP-1 receptor agonist and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24–36 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~12–18 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — tirzepatide's tryptophan and methionine residues are prone to photo-oxidation. | Always keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended for the unreconstituted powder. −20°C is standard for long-term storage; −80°C extends stability further if available. Never freeze a reconstituted solution — that damages the peptide. | Freeze from the start if you won't use it within 3 months. |
| Oxidation Sensitivity | Tirzepatide contains both methionine and tryptophan residues that are vulnerable to oxidation if the vial seal is broken or the powder is exposed to air. | Keep the aluminum crimp cap intact until ready to reconstitute, and minimize air exposure during handling. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a humid kitchen or bathroom, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
This guide is for informational purposes only and is not medical advice; always follow the instructions provided by your supplier.
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 2–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 10–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Certificate of Analysis (COA)
Independent lab test reports are available for Tirzepatide 5mg and 10mg batches. Each certificate provides batch-level verification details, including measured content, purity result, analysis date, and report documentation.
Tirzepatide 10mg
Certificate of Analysis available
Click any certificate preview to enlarge the full Certificate of Analysis.
Donald S.
- April 30, 2026
Dual-receptor binding panel, GIPR and GLP-1R. Matched our reference curves.
Madelyn M.
- March 9, 2026
We needed a dual agonist to sit between our selective GLP-1 reference and the triple agonist in a structure-activity series. This filled that slot. The whole point was the comparison and it held up.
Josephine F.
- February 12, 2026
After working with a lot of lipidated peptides, the C20 diacid handling here is unremarkable in the best way — dissolves, stays in solution, doesn't surprise you. Reliable.
Trinity H.
- February 8, 2026
Reorder. β-cell insulin secretion assays. Consistent across the board.
Melody D.
- January 21, 2026
The catalog doesn't pretend this is a weight-loss product, which sounds like a low bar but apparently isn't. Researcher-facing language, receptor pharmacology framing, no before-and-after nonsense. That alone put this above most of what I found searching.
Enndy
- January 2, 2026
The catalog doesn't pretend this is a weight-loss product, which sounds like a low bar but apparently isn't. Researcher-facing language, receptor pharmacology framing, no before-and-after nonsense. That alone put this above most of what I found searching.
Tirzepatide simultaneously activates two incretin receptors — GLP-1R and GIPR — both G protein-coupled receptors expressed on pancreatic β-cells, hypothalamic appetite centers, and metabolic tissues. The dual activation produces stronger insulin secretion, enhanced anorexigenic signaling at central appetite centers, slowed gastric emptying, and improved white adipose tissue function. Recent pharmacology research suggests tirzepatide is an "imbalanced" dual agonist with somewhat greater GIP than GLP-1 receptor occupancy at therapeutic concentrations.
Number of receptors targeted. Tirzepatide is a dual receptor agonist (GLP-1 + GIP). Retatrutide is an investigational triple receptor agonist (GLP-1 + GIP + glucagon receptors), still in clinical development. Early Retatrutide trials suggest somewhat larger weight loss than tirzepatide, though the safety profile and long-term outcomes are still being characterized. Different generations of incretin-based research.
Earlier research had suggested GIP receptor activation might be problematic in diabetes — leading to skepticism about adding GIP to GLP-1 therapy. Tirzepatide's clinical performance contradicted that assumption. GIP receptor activation appears to enhance white adipose tissue function, contribute to central anorexigenic signaling at hypothalamic centers, and synergize with GLP-1 effects on pancreatic insulin secretion. The combined activation produces effects greater than pure GLP-1 monotherapy.
The C20 dicarboxylic acid fatty acid attachment via a γ-glutamic acid spacer is the technically demanding, expensive part of synthesis. Cheap producers routinely deliver under-conjugated material, fatty acid attached at wrong positions, or unmodified peptide mislabeled as tirzepatide. The international counterfeit GLP-1 market complicates legitimate sourcing further — health authority safety alerts have documented fake and adulterated tirzepatide across multiple jurisdictions.
Eli Lilly developed tirzepatide (originally LY3298176) through clinical trials in the late 2010s and early 2020s. FDA approved Mounjaro for type 2 diabetes in May 2022, the first dual GIP/GLP-1 receptor agonist approved in the US. Zepbound followed for chronic weight management in November 2023, with the obstructive sleep apnea indication added December 2024. Approvals in EU, Canada, and Australia followed similar timelines.
Tirzepatide is not currently named on the WADA Prohibited List. The compound's mechanism — dual incretin receptor agonism affecting glucose and appetite regulation — doesn't fit standard performance-enhancing categories. Athletes subject to drug testing should consult their governing body's specific rules, as anti-doping rules can include unspecified substances under broad metabolic modulator categories.
Mounjaro (the diabetes brand name from Eli Lilly), Zepbound (the obesity/OSA brand name from Eli Lilly), and the development code LY3298176. There is no generic tirzepatide available in the US as of 2026, with patent protection extending into the late 2030s. CAS number 2023788-19-2.
Type 2 diabetes pharmacology and obesity research lead clinical volume. Beyond approved indications, active research includes obstructive sleep apnea (recently approved), MASLD/MASH (liver disease), chronic kidney disease (SURPASS-KIDNEY), cardiovascular outcomes (SURPASS-CVOT trial ongoing), and emerging research in Alzheimer's disease and Parkinson's disease where dual incretin effects on neuroinflammation are being investigated.
Tirzepatide is engineered to mimic both natural incretin hormones simultaneously. Natural GIP and GLP-1 are both released by the gut in response to nutrient ingestion, but they signal through different receptors and have different physiological roles. Tirzepatide combines structural elements of both natural peptides with engineered modifications for stability and combined receptor activity. The fatty acid attachment provides the long half-life that natural GIP and GLP-1 lack.
Dual mechanism producing larger magnitude of effect. Most prior obesity and diabetes drugs targeted single mechanisms — single receptors, single hormonal pathways, single metabolic targets. Tirzepatide's dual GIP/GLP-1 agonism produces pharmacological effects that exceed single-mechanism approaches by clinically meaningful margins. The 22-26% weight loss in the SURMOUNT trials is mechanistically distinct from anything achievable with prior obesity pharmacotherapy.
Researchers investigating dual incretin receptor pharmacology, GIP/GLP-1 co-agonism, and obesity biology consistently examine Tirzepatide alongside compounds that target overlapping or complementary metabolic pathways. Semaglutide is the defining clinical comparison — the SURMOUNT-5 head-to-head trial established Tirzepatide's 47% greater relative weight loss over Semaglutide (20.2% vs 13.7%), making these two the central pharmacological comparison in modern obesity research; researchers studying the incretin receptor spectrum examine both to isolate the specific contribution of GIP receptor co-activation beyond pure GLP-1 agonism. Retatrutide extends the comparison to triple receptor agonism — adding glucagon receptor activation on top of GLP-1 and GIP produces Phase 3 weight loss data of 28.7%, and researchers mapping the dose-response relationship between receptor breadth and metabolic effect examine all three compounds across the single/dual/triple agonist spectrum simultaneously. AICAR activates AMPK through cellular energy sensing rather than incretin receptor signaling — a mechanistically distinct metabolic research tool that researchers examining non-hormonal vs hormonal approaches to fat oxidation and insulin sensitivity often study alongside GLP-1/GIP agonists. HGH Fragment 176-191 and AOD 9604 target lipolysis through growth hormone-derived mechanisms — useful non-incretin fat metabolism reference compounds when researchers need to isolate GLP-1/GIP specific effects from general lipolytic activity. 5-Amino-1MQ inhibits NNMT and addresses adipose tissue NAD+ metabolism — a peripheral metabolic mechanism that complements incretin-based approaches for researchers studying comprehensive obesity biology from multiple mechanistic angles.
Related Products
